Arich Enterprise Co (4173) Fair Value & Analysis
Healthcare · TW · Market cap 1.3B TWD
Fair value as of: Jul 21, 2026
From 15 valuation models · updated 20 days ago
Share price −1.9% over the past month.
A solid business, screening 38% undervalued on our models.
What matters now
- The price is below even our cautious bear case (18.33 TWD). The market is more pessimistic than our downside scenario.
- Solid quality (51/100) at a price below fair value, the discount is the argument here, not the business quality.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 21, 2026.
How to read this chart
60‑month range 15.58 TWD – 27.40 TWD · fair‑value band 18.33 TWD – 30.55 TWD · the 17.75 TWD price screens below the 24.44 TWD fair value. Dashed = 300-day average. As of Jul 21, 2026.
Analysis
Arich Enterprise Co (4173) currently trades at 17.75 TWD, while our model-based Fair Value estimate is 24.44 TWD, implying the stock looks roughly 37.7% undervalued today. The Quality Score stands at 51/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Arich Enterprise Co generated revenue of 1.6B TWD at a net margin of 4.9%. Revenue grew 4.5% year over year. It earns a return on equity of 4.1%. The balance sheet holds a net cash position of 225M TWD. Fundamentals as of Jul 21, 2026
Our scenario range runs from 18.33 TWD (bear case) to 30.55 TWD (bull case); at 17.75 TWD, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 31% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -15% fair-value upside, at 38%, 4173 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 15 models by family
Widest divergence: DCF Models (39.42 TWD) versus Earnings-Based (10.29 TWD). Highest evidence: Residual Income (76).
Notify me when 4173 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 21, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 47 · Market factors (momentum, volatility) 40
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Arich Enterprise Co., Ltd. engages in the marketing, promotion, and distribution of pharmaceuticals in Taiwan. It offers sales promotion for pharmaceutical products; warehousing and logistics, and processing services.
Full company description
Arich Enterprise Co., Ltd. engages in the marketing, promotion, and distribution of pharmaceuticals in Taiwan. It offers sales promotion for pharmaceutical products; warehousing and logistics, and processing services. The company provides distribution and logistics services, including assists manufacturers with bidding processes; inventory management, order processing, invoicing, goods delivery, collection, customer complaint handling, and provides integrated pharmaceutical distribution services. In addition, it offers activities, such as hospital tender and bidding; pharmaceutical pricing negotiations; cold chain, clinical trial drug, and controlled drugs management; information, and financial flow. Arich Enterprise Co., Ltd. was founded in 1969 and is based in New Taipei City, Taiwan.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Arich Enterprise Co reported revenue of 1.5B TWD in FY2025 versus 946M TWD in FY2021, a compound +13.1%/yr. Reported net income was 86.8M TWD in FY2025, compounding +11.9%/yr from FY2021.
Watch 4173: get an alert when its fair value changes →
Peer Group
Pharmaceutical Retailers · 62 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Pharmaceutical Retailers median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate (as of Jul 21, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| JD Health International Inc 6618 | HK$39.20 | HK$33.28 | -15% |
| Raia Drogasil S.A RADL3 | R$18.20 | R$15.58 | -14% |
| Yifeng Pharmacy Chain Co 603939 | ¥23.43 | ¥29.07 | +24% |
| DaShenLin Pharmaceutical Group 603233 | ¥18.23 | ¥23.86 | +31% |
| Corporativo Fragua, S.A. FRAGUAB | 463.00 MXN | 821.18 MXN | +77% |
| LBX Pharmacy Chain Joint Stock Company 603883 | ¥12.74 | ¥10.57 | -17% |
| MedPlus Health Services Limited MEDPLUS | ₹690.20 | ₹379.25 | -45% |
| Yixintang Pharmaceutical Group 002727 | ¥11.46 | ¥9.45 | -18% |
| Anhui Huaren Health Pharmaceutical Co 301408 | ¥14.40 | ¥10.05 | -30% |
| Apotea AB APOTEA | kr 74.75 | kr 43.95 | -41% |
Compare Arich Enterprise Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Arich Enterprise Co (4173) overvalued or undervalued?
What is the fair value of 4173?
What is the quality score of 4173?
What is the revenue of Arich Enterprise Co (4173)?
What is the net profit margin of 4173?
Does Arich Enterprise Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Arich Enterprise Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.